Altria Narrows 2026 EPS Guidance to $5.61–$5.72, Raises Capex for Manufacturing Consolidation
MO sits 33% above its 52-week low of $54.7.
Summary
Altria reported Q2 adjusted EPS of $1.48, up 2.8%, and narrowed its 2026 adjusted EPS guidance to $5.61–$5.72, raising the lower end. Capex guidance was increased to fund manufacturing consolidation, while the company continued aggressive share buybacks.
Key Events · Earnings and Guidance · MO
-
Q2 Adjusted EPS Beats, Guidance Raised
Adjusted diluted EPS of $1.48 grew 2.8% YoY; full-year guidance narrowed to $5.61–$5.72 (3.5%–5.5% growth), with the lower end raised from prior range.
-
Capex Increased for USSTC Consolidation
2026 capex guidance raised to $375M–$450M (from $300M–$375M) to support consolidation of USSTC manufacturing, a one-time investment expected to improve long-term efficiency.
-
Share Repurchases Continue
Repurchased 5.3M shares for $335M in H1 2026; $665M remaining under $2B program expiring Dec 31, 2026.
-
Smoke-Free Portfolio Progress
Helix on! PLUS resumed shipments in select states with national expansion planned for Q3; new flavors (Blueberry Mint, Mango Pineapple) coming in Q4.
Analysis · MO · Manufacturing
Altria delivered a solid quarter with adjusted EPS growth of 2.8% and raised the lower end of its full-year guidance, signaling confidence in its smoke-free transition and traditional tobacco pricing power. The capex increase to support USSTC consolidation is a one-time investment that should drive future efficiencies. Share repurchases continue to return capital, but the oral tobacco segment remains under pressure from share losses and volume declines.
At the time of this filing, MO was trading at $72.99 on NYSE in the Manufacturing sector, with a market capitalization of approximately $125.1B. The 52-week trading range was $54.70 to $77.06. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.